Kodiak Sciences Announces Additional Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation, and D

By In The News
February 8, 2020 in The Headlines

Recommended Posts

In The News

Posted February 8, 2020

- Share

Posted February 8, 2020

PALO ALTO, Calif., Feb. 8, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced promising safety, efficacy and durability data from the...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  222618
2. Jaydee
  18144
3. deicer
  13666
4. Kip Powick
  12356
5. dagger
  9615
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  273.1k
- Total Posts
  
  566.7k

Sign In

Kodiak Sciences Announces Additional Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation, and D

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support